President Trump considers imposing retaliatory economic sanctions on Chinese products.

Peter Prince

2018-01-10 08:40:00 Wed ET

President Trump considers imposing retaliatory economic sanctions on Chinese products and services in direct response to China's theft and infringement of U.S. intellectual property. Trump's retaliatory trade sanctions may involve tariffs, quotas, embargoes, and other restrictions on China's investments in U.S. companies. This punitive penalty arises as part of a recent Trade Act Section 301 probe into China's recent regulations that induce U.S. multinational corporations to establish onshore IT data centers. These regulations force unfair intellectual property and technology transfer from these U.S. multinational corporations to their Chinese counterparts. Without such technology transfer, the use and implementation of U.S. patents and trademarks would otherwise involve egregious infringement at the expense of U.S. firms and other innovators.

Recent empirical evidence suggests that this unfair technology transfer may be the root cause of both billions of dollar losses in corporate revenue as well as millions of job losses in America. In addition to intellectual property theft and infringement, the Trump administration also accuses China of currency manipulation. Over the years, China has been accumulating substantial dollar reserves in the form of U.S. Treasury bonds for better renminbi devaluation. This deliberate devaluation leads to more competitive Chinese export prices and thus better low-cost product sales abroad. The Trump administration needs to consider retaliatory trade sanctions on China in order to eradicate trade deficits with better fiscal discipline.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

America faces income inequality, political polarization, and dysfunctional governance.

Rose Prince

2018-05-17 07:41:00 Thursday ET

America faces income inequality, political polarization, and dysfunctional governance.

Has America become a democratic free land of crumbling infrastructure, galloping income inequality, bitter political polarization, and dysfunctional governa

+See More

Financial institutions benefit from higher equity risk premiums and interest rate spreads.

Charlene Vos

2017-04-01 06:40:00 Saturday ET

Financial institutions benefit from higher equity risk premiums and interest rate spreads.

With the current interest rate hike, large banks and insurance companies are likely to benefit from higher equity risk premiums and interest rate spreads.

+See More

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Monica McNeil

2019-01-04 11:41:00 Friday ET

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution. Xi sends a congratulatory message to mark 40 years sin

+See More

Most sustainably successful business leaders make a mark in the world, create a positive impact, and challenge the status quo.

Peter Prince

2020-08-12 07:25:00 Wednesday ET

Most sustainably successful business leaders make a mark in the world, create a positive impact, and challenge the status quo.

Most sustainably successful business leaders make a mark in the world, create a positive impact, and challenge the status quo. Jerry Porras, Stewart Emer

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

The Trump fiscal trifecta of lower income taxation, new infrastructure, and deregulation has yet to run its natural course.

Becky Berkman

2017-04-25 06:35:00 Tuesday ET

The Trump fiscal trifecta of lower income taxation, new infrastructure, and deregulation has yet to run its natural course.

This nice and clear infographic visualization helps us better decipher the main memes and themes of President Donald Trump's first 100 days in office.

+See More